PRTA Prothena Corp Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTA

Price (delayed)

$9.29

Market cap

$486.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.81

Enterprise value

$164.55M

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 63
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 25

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The quick ratio has increased by 35% since the previous quarter and by 18% year-on-year
Prothena's debt has decreased by 25% YoY and by 9% from the previous quarter
The net income has grown by 38% from the previous quarter but it has contracted by 37% YoY
The company's EPS rose by 38% QoQ but it fell by 37% YoY
Prothena's revenue has plunged by 58% YoY
The company's gross profit has shrunk by 58% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.prothena.com/
Peers: ALKS ALNY AMRN

Key stats

What are the main financial stats of PRTA

PRTA stock price

How has the Prothena stock price performed over time
Intraday
4.15%
1 week
-6.91%
1 month
-13.9%
1 year
90.37%
YTD
-2.72%
QTD
-4.42%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$57.94M
Gross profit
$57.94M
Operating income
-$119.02M
Net income
-$151.18M
Gross margin
100%
Net margin
-260.9%
The operating margin has dropped by 104% year-on-year but it has soared by 91% since the previous quarter
Prothena's net margin has soared by 90% from the previous quarter
Prothena's revenue has plunged by 58% YoY
The company's gross profit has shrunk by 58% YoY

Price vs fundamentals

How does PRTA's price correlate with its fundamentals

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
1.6
P/S
8.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
The company's EPS rose by 38% QoQ but it fell by 37% YoY
PRTA's price to book (P/B) is 57% lower than its 5-year quarterly average of 3.6 and 3.8% lower than its last 4 quarters average of 1.6
The company's equity fell by 29% YoY but it rose by 11% QoQ
PRTA's price to sales (P/S) is 84% lower than its 5-year quarterly average of 50.6 and 76% lower than its last 4 quarters average of 34.6
Prothena's revenue has plunged by 58% YoY

Efficiency

How efficient is Prothena business performance
The ROE has plunged by 131% YoY but it has increased by 32% from the previous quarter
Prothena's return on assets has shrunk by 119% YoY but it has increased by 32% QoQ
The company's return on sales has shrunk by 119% YoY but it has surged by 91% QoQ

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
PRTA's current ratio is up by 35% since the previous quarter and by 16% year-on-year
The quick ratio has increased by 35% since the previous quarter and by 18% year-on-year
Prothena's debt is 98% less than its equity
Prothena's debt to equity has decreased by 33% QoQ
The company's equity fell by 29% YoY but it rose by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.